Preliminary Data Show Improved Responses with Cetuximab Plus

Jayesh Desai, MBBS, FRACP, reports prior phase 1 data on the use of divarasib monotherapy in KRAS G12C–mutated CRC and early efficacy, safety, and presents pharmacokinetic data from the use of divarasib plus cetuximab from a phase 1 trial.

Related Keywords

Australia , Melbourne , Victoria , Roche Genentech , Pierre Fabre , Jayesh Desai , Astrazeneca Medimmune , Daiichi Sankyo Europe Gmb , Phasei Early Drug Development Program , University Of Melbourne , Merck Kga , Novartis , Glaxosmithkline , Amgen , Sir Peter Maccallum Department Of Oncology , Peter Maccallum Cancer Centre , Merck Kgaa , Boehringer Ingelheim , Bristol Myers Squibb , Pfizer , Early Drug Development Program , Peter Maccallum Cancer , Sir Peter Maccallum Department , Daiichi Sankyo Europe Gmbh , Cetuximab Plus Divarasib , Bbs , Racp , Patients With Kras G12c Mutated Colorectal Cancer ,